Forte Biosciences, Inc. financial data

Symbol
FBRX on Nasdaq
Location
Dallas, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 774% % 69%
Return On Equity -76% % 50%
Return On Assets -66% % 45%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12,526,935 shares 757%
Common Stock, Shares, Outstanding 12,523,845 shares 758%
Entity Public Float $18,300,000 USD -10%
Common Stock, Value, Issued $13,000 USD 1200%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $11,696,000 USD -27%
Operating Income (Loss) $53,437,000 USD -50%
Net Income (Loss) Attributable to Parent $51,742,000 USD -51%
Earnings Per Share, Basic 0 USD/shares 100%
Earnings Per Share, Diluted 0 USD/shares 100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $93,414,000 USD 471%
Cash, Cash Equivalents, and Short-term Investments $58,400,000 USD
Assets, Current $95,412,000 USD 440%
Property, Plant and Equipment, Net $148,000 USD 72%
Other Assets, Noncurrent $1,529,000 USD 696%
Assets $97,089,000 USD 441%
Accounts Payable, Current $5,491,000 USD 6.4%
Accrued Liabilities, Current $7,501,000 USD 119%
Liabilities, Current $12,992,000 USD 51%
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,000 USD -700%
Retained Earnings (Accumulated Deficit) $198,585,000 USD -35%
Stockholders' Equity Attributable to Parent $84,097,000 USD 798%
Liabilities and Equity $97,089,000 USD 441%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,355,000 USD -55%
Net Cash Provided by (Used in) Financing Activities $2,322,000 USD -28925%
Net Cash Provided by (Used in) Investing Activities $36,289,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 12,523,845 shares 758%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $23,612,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $93,414,000 USD 471%
Deferred Tax Assets, Valuation Allowance $24,501,000 USD 32%
Deferred Tax Assets, Gross $24,501,000 USD 32%
Depreciation $13,000 USD 44%
Payments to Acquire Property, Plant, and Equipment $61,000 USD 917%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $51,749,000 USD -51%
Property, Plant and Equipment, Gross $241,000 USD 94%
Deferred Tax Assets, Operating Loss Carryforwards $7,638,000 USD 17%
Unrecognized Tax Benefits $411,000 USD 64%
Share-based Payment Arrangement, Expense $5,291,000 USD 66%